Prioritising research into age‐related macular degeneration

descriptionPublicationkeyboard_double_arrow_right Article 01 May 2019 English Publisher:WileyJournal:Prescriber, volume 30, pages 10-17 (issn: 0959-6682, eissn: 1931-2253,

Copyright policy )

Authors: Mark Greener;

doi: 10.1002/psb.1759

Prioritising research into age‐related macular degeneration

- Summary
- Metrics

Abstract

As life expectancy increases, the number of people living with age‐related macular degeneration (AMD) is set to rise dramatically, meaning it could become the next public health crisis. Existing treatments are of limited benefit, but researchers are exploring several avenues that could lead to new therapies.

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	1
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average